SOM Biotech (SOM), a clinical-stage drug discovery and development company based on a unique and proprietary artificial intelligence (AI) platform, has appointed Silvia Panigone PhD, MBA as Executive Chair of the Board of SOM.

Dr Raul Insa, Founder and President of the Board at SOM, said: “We are pleased and honoured to have Silvia Panigone joining SOM as Executive Chair. She brings to SOM an important and extensive experience in the Corporate Strategy at global level, having served as CEO, COO and other C-level positions in private and public biotech and pharma companies, as well as having served as Director in Investment Banking firms and Venture Capitalist groups.”

“I thank Raul and SOM Board for the privilege to fulfil this role and I am enthusiastic to support the Company in its next growth step,” said Silvia Panigone. “My goal is to strengthen SOM’s Corporate Governance, to open to the US market and prepare it for a possible listing on the NASDAQ within the next couple of years to establish a US presence. I have been following SOM for several years as a small investor and I appreciated the uniqueness of SOM’s AI platform with its high, demonstrated, clinical predictivity and the strong commitment and dedication of Raul and his team. I’ll do my utmost best to make SOM Biotech successful for the benefit of patients and all of SOM’s stakeholders.”